Evidence mapPaperPMID 35059112Full record

ArticleACS medicinal chemistry letters2022

Antivirals against (Re)emerging Flaviviruses: Should We Target the Virus or the Host?

María-Jesús Pérez-Pérez, Juan-Carlos Saiz, Eva-María Priego, Miguel A Martín-Acebes

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  2. Unraveling flavivirus pathogenesis: from bulk to single-cell RNA-sequencing strategies.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

María-Jesús Pérez-PérezInstituto de Química Médica (IQM-CSIC), c/Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0003-1336-7760
Juan-Carlos SaizDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC), Carretera de A Coruña km 7.5, 28040 Madrid, Spain.
Eva-María PriegoInstituto de Química Médica (IQM-CSIC), c/Juan de la Cierva 3, E-28006 Madrid, Spain.ORCID https://orcid.org/0000-0001-9470-4508
Miguel A Martín-AcebesDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC), Carretera de A Coruña km 7.5, 28040 Madrid, Spain.
Instituto de Química Médica · ESInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID pandemic has evidenced how vulnerable we are to emerging infectious diseases and how short our current armamentarium is. Flavivirus, single stranded RNA viruses transmitted by arthropods, are considered a global health challenge. No drugs to treat these infections have been approved. In this Viewpoint, we analyze the advantages and disadvantages of two different, but probably also complementary, therapeutic approaches: virus-targeting antivirals and host-targeting drugs.

Identifiers

PMID35059112
PMCPMC8762743
OpenAlexW4200453791

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.